Disclosure(s)

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities In the past five years and the dates of the name changes.

Greenscape Laboratories, Inc. – May 23, 2014 – Present
HD Retail Solutions, Inc. - June 10 2009, to May 22, 2014
Greenwind Power Corp., USA- April 8, 2004 to June 10, 2009

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1; 1311 East La Rua Street
Address 2: Pensacola, FL
Address 3: 32501
Phone; (800) 451-6133
Fax (800)701-5744
Email: info@hdretailsolutions.com
Website(s): www.hdretailsolutions.com

IR Contact

N/A

3) Security Information

Trading Symbol: MJLB
Exact title and class of securities outstanding: Common Shares
CUSIP: 42205X102
Par or Stated Value: 0.001
Total shares authorized: 60,000,000 as of: Dec 31, 2014
Total shares Outstanding: 54,152,718 as of: Dec 30, 2014**

Shares were issued in connection with an Agreement with Sylios Corp. on July 9 but were subsequently canceled and rescinded in lieu of promissory obligations.

Additional class of securities (if necessary)

N/A

Transfer Agent
Name: Registrar & Transfer Co.
Address 1: 10 Commerce Dr.
Address 2: Cranford, NJ
Address 3: 07016
Phone: (800) 525-7686
Is the Transfer Agent registered under the Exchange Act?* Yes: X No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below are any events, in chronological order that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

1) Apr 21, 2014 – 10,000,000 Common Restricted Shares issued © par to James R.J. Scheltema for the asset purchase agreement with Greenscape Laboratories, Inc. of Wyoming.
2) Apr 22, 2014 – 3,500,000 Common Restricted Shares issued © par to Mentat Holdings, LLC via debt reduction/conversion of debt held by a third party.
3) May 5, 2014 – 1,000,000 Common Restricted Shares issued © par to Alexander Scheltema via debt reduction/conversion of debt held by a third party.
4) May 5, 2014 – 1,000,000 Common Restricted Shares issued © par to Sharon Irni via debt reduction/conversion of debt held by a third party.
5) May 5, 2014 – 1,000,000 Common Restricted Shares issued © par to PAG Group, LLC via debt reduction/conversion of debt held by a third party.
6) May 5, 2014 – 1,000,000 Common Restricted Shares issued © par to James Scheltema via debt reduction/conversion of debt held by a third party.
7) Jun 6, 2014 – 500,000 Common Restricted Shares issued © par to Bethany Sherman for General Administrative Expense.

A. The nature of each offering (*e.g.,* Securities Act Rule 504, intrastate, etc.);

Number 1 Asset Purchase Agreement;
Number 7 issued from treasury for Compensation.
Numbers 2, 3, 4, 5 and 6 conversions to common shares pursuant to terms of debt instrument.

All of the listed transactions were private, *i.e.,* there were no public offerings.

B. Any jurisdictions where the offering was registered or qualified;

None

C. The number of shares offered;

None

D. The number of shares sold;

None

E. The price at which the shares were offered, and the amount actually paid to the issuer;

None

F. The trading status of the shares; and

Number 1 Asset Purchase Agreement; Numbers 7 and 8 issued from treasury for Compensation. These issuances are each made with Restricted Common Shares and contain a restrictive legend.

These issuance are made with Freely Trading Common Shares and contain no restrictive legends. However, issuances made to James R. J. Scheltema remain subject to certain other restrictions on disposition, e.g., restriction on selling more than 1% of the total outstanding number of shares during a 90 day rolling period.

Numbers 2, 3, 4, 5 and 6 conversions to common shares pursuant to terms of debt instrument.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

See F, above.

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end, ("Annual Report", "Quarterly Report" or Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otciq.com in the field below.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal-year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuers business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. A description of the issuer's business operations;

Greenscape Laboratories, Inc. was founded for the purpose of ensuring the safety of cannabis by providing advanced assistance in testing consumable products for both chemical or foreign contaminants. We believe that testing is extremely important to all users - both medical and recreational.

B. Date and State (or Jurisdiction) of Incorporation:

February 14, 1989, Nevada

C. The issuers primary and secondary SIC Codes;

7389 - Business services, Misc.

D. The issuer's fiscal year end date;

December 31

E. Principal products or services, and their markets;

Greenscape Laboratories, Inc. principal product/service is testing cannabis for both chemical and foreign contaminants.

The principal market for its services is the pacific northwest, i.e., Washington and Oregon, although it believes this market will expand quickly with the rising tide of legalization of marijuana use among the states.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

1) A conditional consulting agreement was entered into with Iron Labs in early November concerning the location of potential properties to locate laboratories in Florida in the event Amendment 2 was passed permitting the use of medical marijuana in Florida. Although the Amendment failed to pass with 60% of the vote (it passed with only 58%+), Iron City and Greenscape Laboratories look forward to continuing to negotiate future agreements, when and where economically viable.
2) Reciprocal consulting agreements were entered into with Sylios Corp. and its chief executive officer on July 9 for a fixed quantity of stock. These agreements were amended as of July 9 in the form of promissory obligations.

8) Officer, Director and Control Person

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officer, Director and Control Person. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

James R. J. Scheltema

B. Legal/Disciplinary History: Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders, Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

James R.J. Scheltema, CEO, President, Secretary and Director of the company located 1311 East La Rua Street, Pensacola, FL 32501. Currently he is the only affiliate with more than 10% of the common shares outstanding.

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

John T. Root, Jr.
ATTORNEY AT LAW
P.O. Box 5666
Jacksonville, Arkansas 72078
Phone: (501) 529-8567
Fax: (501) 325-1130
j.root.5013@gmail.com

Accountant or Auditor

N/A

Investor Relations Consultant

N/A

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

N/A

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities). The certifications shall follow the format below:


I, James R.J Scheltema certify that:

1. I have reviewed this financial statement for the quarter ending June 30, 2014 and Disclosures of Greenscape Laboratories, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for the periods presented in this disclosure statement.

February 12, 2015



James R. J. Scheltema
President/Secretary/Treasurer/Director

Greenscape Laboratories Inc.
4th Qtr 2014 Balance Sheet
As of December 31, 2014

	Dec 31, 14	Sep 30, 14	$ Change
ASSETS			
Current Assets			
Checking/Savings			
Wells Fargo	2,552	2,316	236
Total Checking/Savings	2,552	2,316	236
Accounts Receivable			
Accounts Receivable	200,000	200,000	
Total Accounts Receivable	200,000	200,000	
Other Current Assets			
Pre-Paid Expenses	150,000	150,000	
Total Other Current Assets	150,000	150,000	
Total Current Assets	352,552	352,316	236
Fixed Assets			
Lab Equipment	15,000	15,000	
Total Fixed Assets	15,000	15,000	
Other Assets			
Intangible Assets			
Amortization Accumulated	(3,750)	(2,500)	(1,250)
Intangible Assets - Other	50,000	50,000	
Total Intangible Assets	46,250	47,500	(1,250)
Total Other Assets	46,250	47,500	(1,250)
TOTAL ASSETS	**413,802**	**414,816**	**(1,014)**
LIABILITIES & EQUITY			
Liabilities			
Current Liabilities			
Other Current Liabilities			
Accounts Payable	200,475	200,475	
Unearned Income	150,000	150,000	
Total Other Current Liabilities	350,475	350,475	
Total Current Liabilities	350,475	350,475	
Long Term Liabilities			
Loan From Officer	20,834	15,106	5,728
Notes Payable	112,668	123,798	(11,130)
Total Long Term Liabilities	133,501	138,903	(5,402)
Total Liabilities	483,977	489,379	(5,402)
Equity			
Additional Paid in Capital	19,443	19,443	

	Dec 31, 14	Sep 30, 14	$ Change
Common Shares	65,283	54,153	11,130
Retained Earnings	(112,538)	(112,538)	
Net Income	(42,363)	(35,621)	(6,742)
Total Equity	(70,175)	(74,563)	4,388
TOTAL LIABILITIES & EQUITY	**413,802**	**414,816**	**(1,014)**

Greenscape Laboratories Inc.
Profit & Loss
October through December 2014

	Oct - Dec ...
Income	
Expense	
Amortization Expens...	1,250
General Administrati...	917
Officer Compensation	4,500
Telephone	75
Total Expense	6,742
Net Income	**(6,742)**

Greenscape Laboratories Inc.
Statement of Cash Flows
October 1 through December 31, 2014

	Oct - Dec 14
OPERATING ACTIVITIES	
Net Income	(6,742)
Net cash provided by Operating Activities	(6,742)
INVESTING ACTIVITIES	
Intangible Assets:Amortization Accumulated	1,250
Net cash provided by Investing Activities	1,250
FINANCING ACTIVITIES	
Loan From Officer	5,728
Notes Payable	(11,130)
Common Shares	11,130
Net cash provided by Financing Activities	5,728
Net cash increase for period	236
Cash at beginning of period	2,316
Cash at end of period	**2,552**

Greenscapes Laboratories Inc

EPS Calculation 12/31/2014

		Cumulative Losses Per Share From Inception of Company	Losses Per Share For 4th Qtr 2014
Earnings		$ (154,901.00)	$ (6,742.00)
Beginning Shares O/S	36,152,772		
Ending Shares O/S	65,282,772		
Average Shares O/S	50,717,772		

NET INCOME PER SHARE:

Basic and Diluted Per Share Earnings	$ (0.003054)	$ (0.000133)

Weighted Average Number of Shares Outstanding
During the Period Ending December 31, 2014
Common Stock $.001 Par Value, 500,000,000 shares
Authorized, 65,282,772 Outstanding as of December 31, 2014

The accompanying notes are an integral part to these financial statements.

Greenscape Laboratories, Inc.
Notes to the Financial Statement
December 31, 2015 (unaudited)

1. THE COMPANY

The Issuer was incorporated in the State of Nevada on February 14, 1989; under the name Paramour Productions Inc. on April 11, 1996 the company restated its articles of incorporation. On June 30, 1998 the company changed its name to COM 101, Inc. On June 18, 1999 the company changed its name to Optimal Analytics.com, Inc. On February 7, 2002 the company changed its name to Optimal Ventures, Inc. On April 8, 2004 the Company changed its name to Greenwind Power Corp. USA, and on June 10, 2009 the company changed its name to HD Retail Solutions, Inc.

On May 23, 2014 the company changed its name from HD Retail Solutions, Inc. to Greenscape Laboratories, Inc. with a filing made with the Secretary of State for Nevada. Approval was granted by FINRA and a symbol change granted on June 9, 2014 (from HDRE to MJLB).

The company has entered the market of testing marijuana to determine the ratio and quantities of its component elements and determine the presence of toxins.

2. SIGNIFICANT ACCOUNTING POLICIES

The company's accounting policies conform to United States generally accepted accounting principles and have been consistently applied in the preparation of these financial statements.

The financial statements included herein have not been audited by an independent registered public accounting firm, but include all adjustments (including normal, recurring entries, which are, in the opinion of management, necessary for a fair presentation of the results for such periods,

3. INVESTMENTS

The Company owns certain laboratory equipment, conservatively valued at $15,000 as a result of an asset purchase with Greenscape Laboratories, Inc. of Wyoming. The purchase price was ten million (10,000,000) shares of restricted common stock.

4. INTANGIBLE ASSETS

The Company has applied for a trademark with the US Patent Office for its "lab lion". Approval is pending. The artist was compensated with restricted common shares.

The Company concluded there were no impairments of its intangible assets.

5. NOTES PAYABLE

As of December 31, 2014, the Company has a total of $133,501 outstanding notes payable. $4,129.36 is owed by the company, but has not yet been incorporated into a Note.
On December 10, 2009, the Company issued a note payable to an unrelated party for $65,000. The note is due to mature on December 10, 2010, bears no interest and is convertible at $0.001 per share.
On January 16, 2011, the Company issued a note payable to an unrelated party for $35,000. The note is due to mature on January 16, 2012, bears no interest and is convertible at $0.001 per share.
On January 5, 2012, the Company issued a note payable to an unrelated party for $10,000. The note is due to mature on January 5, 2013, bears no interest and is convertible at $0.001 per share.
On July 8, 2013, the Company issued a note payable to John A Stange Jr. for $5,675; the note is due to mature on July 8, 2014, bears no interest and is convertible at $0.001 per share.

On July 1, 2013 the Company issued a note payable to an unrelated party for $1,985. The note is due to mature on July 8, 2014, bears no interest and is convertible at $0.001 per share.
On February 27, 2014, the Company issued a note payable to an unrelated party for $2,500. The note is due to mature on February 27, 2015, bears no interest and is convertible at $0.001 per share.
On May 1, 2014, the Company issued a note payable to an unrelated party for $2,500. The note is due to mature on May 1, 2015, bears no interest and is convertible at $0.001 per share.
On May 1, 2014, the Company issued a note payable to an unrelated party for $7,500. The note is due to mature on May 1, 2015, bears no interest and is convertible at $0.001 per share.
On June 1, 2014, the Company issued a note payable to an unrelated party for $1,000. The note is due to mature on June 1, 2015, bears no interest and is convertible at $0.001 per share.

Terms of each note payable is described below

Note Description	Issue Date	Maturity Date	Interest Rate	Conversion Rate	Original $Amount at Issue Date	$ Amount converted to Common Stock	$Amount outstanding as at June 30, 2014
Unsecured Note Payable (NP#1)	12/10/09	Due on Demand	0%	$0.0010	$ 65,000	$ 2,500 1st Qtr; $ 9,288.50 2nd Qtr	$ 55,712
Unsecured Note Payable (NP#2)	01/16/11	Due on Demand	0%	$0.0010	$ 35,000		$ 35,000
Unsecured Note Payable (NP#3)	01/05/12	Due on Demand	0%	$0.0010	$ 10,000		$ 10,000
Unsecured Note Payable (NP#4)	07/08/13	Due on Demand	0%	$0.0010	$ 5,675		$ 5,675
Unsecured Note Payable (NP#5)	07/08/13	Due on Demand	0%	$0.0010	$ 1,985		$ 1,985
Unsecured Note Payable (NP#6)	05/01/14	Due on Demand	0%	$0.0010	$ 2,500		$ 2,500
Unsecured Note Payable (NP#7)	05/01/14	Due on Demand	0%	$0.0010	$ 7,500		$ 7,500
Unsecured Note Payable (NP#8)	06/01/14	Due on Demand	0%	$0.0010	$ 1,000		$ 1,000
TOTAL OUTSTANDING							**$119,372**
TOTAL OUTSTANDING LOAN FROM SMALL CAP DEVELOPMENT, INC.							
Loan from Director	10/28/13	Due on Demand	0%	$0.0010	$ 500.00		$ 500.00
Loan from Director	01/29/14	Due on Demand	0%	$0.0010	$ 800.00		$ 800.00
Loan from Director	02/13/14	Due on Demand	0%	$0.0010	$ 1,000.00		$ 1,000.00
Loan from Director	06/01/14	Loan from Director	0%	$0.0010	$ 8,676.64		$ 8,676.64
Loan from Director	12/31/14	Loan from Director	0%	$0.0010	$ 5,728.00		$ 5,728.00
TOTAL							**$ 16,704.64**

OUTSTANDING LOAN FROM DIRECTOR							

5. SHARE CAPITAL FOR COMPENSATION

On June 6, 2014, the Company issued 500,000 Common Restricted Shares at par for General Administrative Expense pursuant to a letter of intent entered into with Oregon Growers Analytical, LLC. No shares were issued for compensation in the 4th Quarter.

6. GOING CONCERN

The accompanying financial statements have been prepares on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, during the three month period ended December 31, 2014, the Company incurred a loss of $6,742. The Company has an accumulated deficit of $112,538.

7. SUBSEQUENT EVENTS

None.